Advertisement

Use of Lactobacillus probiotics for bacterial genitourinary infections in women: A review

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background: Lactobacilli are the dominant bacteria of the vaginal flora and possess antimicrobial properties that regulate other urogenital microbiota. Incomplete cure and recurrence of genitourinary infections lead to a shift in the local flora from a predominance of lactobacilli to coliform uropathogens. Use of Lactobacillus-containing probiotics to restore commensal vaginal flora has been proposed for the treatment and prophylaxis of bacterial urogenital infections.
      Objective: This review summarizes randomized controlled trials that have assessed the therapeutic efficacy and tolerability of lactobacilli in bacterial vaginosis (BV) and urinary tract infection (UTI).
      Methods: Relevant randomized controlled trials published in English were identified through a search of MEDLINE (through November 2007), ClinicalTrials.gov, and the Cochrane Database (second quarter 2007). The search terms included probiotics, Lactobacillus, lactobacilli, urinary, urogenic, bacterial vaginosis, vaginal, colonization, bacteremia, sepsis, pathogenic, taxonomy, diagnosis, and infections.
      Results: Eleven randomized controlled trials were identified that investigated the effects of lactobacilli in the treatment and prophylaxis of bacterial urogenital infections. In the 2 studies that reported a beneficial effect for probiotics in the treatment of BV, cure rates for lactobacilli at 30 days were 60% (P = 0.004) and 88% (P < 0.005), more than double the effect of controls. One trial reported a 35% reduction in recurrent episodes of BV compared with placebo (P = 0.004). Among the 4 trials involving treatment of UTI, 1 reported a 73% reduction in episodes of recurrent UTI compared with the previous year (P = 0.001). Seven studies found no therapeutic effect of lactobacilli in the treatment or prophylaxis of BV or UTI. Only 2 of the identified trials attempted to validate the probiotic dosing strategy by obtaining quantitative evidence of local colonization with lactobacilli and had sufficient power to detect treatment effects, and only 1 trial addressed the stability of the probiotic product at the end of the study.
      Conclusions: Despite enhanced cure rates in some studies, concerns about product stability and limited documentation of strain-specific effects prevent recommendations for the use of Lactobacillus-containing probiotics in the treatment of BV. The results of studies of lactobacilli for the prophylaxis of UTI remain inconclusive as a result of small sample sizes and use of unvalidated dosing strategies.

      Key words

      To read this article in full you will need to make a payment
      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Report of a Joint FAO/WHO Expert Consultation on health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, American Córdoba Park Hotel, Córdoba, Argentina, 1–4 October 20012008 (Accessed February 11,)
        • Parkes GC.
        An overview of probiotics and prebiotics.
        Nurs Stand. 2007; 21: 43-47
        • Ross JJ
        • Boucher PE
        • Bhattacharyya SP
        • et al.
        Considerations in the development of live biotherapeutic produts for clinical use.
        Curr Issues Mol Biol. 2008; 10 (Accessed February 28,): 13-16
        • Forsum U
        • Holst E
        • Larsson PG
        • et al.
        Bacterial vaginosis-a microbiological and immunological enigma.
        APMIS. 2005; 113: 81-90
        • Sweet RL
        Gynnecologic conditions and bacterial vaginosis: Implications for the non-pregnant patient.
        Infect Dis Obstet Gynecol. 2000; 8: 184-190
        • Felis GE
        • Dellaglio F
        Taxonomy of Lactobacilli and Bifidobacteria.
        Curr Issues Intest Microbiol. 2007; 8: 44-61
        • McLean NW
        • Rosenstein IJ
        Characterization and selection of a Lactobacillus species to recolonise the vagina of women with recurrent bacterial vaginosis.
        J Med Microbiol. 2000; 49: 543-552
        • Morelli L
        • Zonenenschain D
        • Del Piano M
        • Cognein P
        Utilization of the intestinal tract as a delivery system for urogenital probiotics.
        J Clin Gastroenterol. 2004; 38: S107-S110
        • Mastromarino P
        • Brigidi P
        • Macchia S
        • et al.
        Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets.
        J Appl Microbiol. 2002; 93: 884-893
        • Reid G
        • Burton J
        Use of Lactobacillus to prevent infection by pathogenic bacteria.
        Microbes Infec. 2002; 4: 319-324
        • Reid G
        • Charbonneau D
        • Erb J
        • et al.
        Oral use of Lactobacillus rhamnosus GR-1 and Lfermentum RC-14 significantly alters vaginal flora: Randomized, placebo-controlled trial in 64 healthy women.
        FEMS Immunol Med Microbiol. 2003; 35: 131-134
        • Cadieux P
        • Burton J
        • Gardiner G
        • et al.
        Lactobacillus strains and vaginal ecology.
        JAMA. 2002; 287: 1940-1941
        • Gardiner GE
        • Heinemann C
        • Bruce AW
        • et al.
        Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L.
        rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin Diagn Lab Immunol. 2002; 9: 92-96
        • Reid G
        • Beuerman D
        • Heinemann C
        • Bruce AW
        Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora.
        FEMS Immunol Med Microbiol. 2001; 32: 37-41
        • Aroutcheva A
        • Gariti D
        • Simon M
        • et al.
        Defense factors of vaginal Lactobacilli.
        Am J Obstet Gynecol. 2001; 185: 375-379
        • Velraeds MM
        • van der Mei HC
        • Reid G
        Inhibition of initial adhesion of uropathogen Enterococcus faecalis by biosurfactants from Lactobacillus isolates.
        Appl Environ Microbiol. 1996; 62: 1958-1963
        • Wilson J.
        Managing recurrent bacterial vaginosis.
        Sex Transm Infect. 2004; 80: 8-11
        • Forsum U
        • Hallén A
        • Larsson PG
        Bacterial vaginosis-a laboratory and clinical diagnostics enigma.
        APMIS. 2005; 113: 153-161
      2. Centers for Disease Control and Prevention; Sexually transmitted diseases treatment guidelines 2002.
        MMWR Recomm Rep. 2002; 51: 1-78
      3. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
        in: Guidance for industry: Bacterial vaginosis–developing antimicrobial drugs for treatment. 2008 (Accessed February 15,)
        • Larsson PG
        • Forsum U
        Bacterial vaginosis-a disturbed bacterial flora and treatment enigma.
        APMIS. 2005; 113: 305-316
        • Austin MN
        • Beigi RH
        • Meyn LA
        • Hillier SL
        Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole.
        J Clin Microbiol. 2005; 43: 4492-4497
        • Anukam KC
        • Osazuwa E
        • Ahonkhai I
        • et al.
        Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: Randomized, double-blind, placebo controlled trial.
        Microbes Infect. 2006; 8: 1450-1454
        • Shalev E
        • Battino S
        • Weiner E
        • et al.
        Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis.
        Arch Fam Med. 1996; 5: 593-596
        • Neri A
        • Sabah G
        • Samra Z
        Bacterial vaginosis in pregnancy treated with yogurt.
        Acta Obstet Gynecol Scand. 1993; 72: 17-19
        • Eriksson K
        • Carlsson B
        • Forsum U
        • Larsson PG
        A double-blind treatment study of bacterial vaginosis with normal vaginal Lactobacilli after an open treatment with vaginal clindamycin ovules.
        Acta Derm Venereol. 2005; 85: 42-46
        • Anukam KC
        • Osazuwa E
        • Osemene GI
        • et al.
        Clinical study comparing Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis.
        Microbes Infect. 2006; 8: 2772-2776
        • Hallén A
        • Jarstrand C
        • Påhlson C
        Treatment of bacterial vaginosis with Lactobacilli.
        Sex Transm Dis. 1992; 19: 146-148
        • Fredricsson B
        • Englund K
        • Weintraub L
        • et al.
        Bacterial vaginosis is not a simple ecological disorder.
        Gynecol Obstet Invest. 1989; 28: 156-160
        • Warren JW
        • Abrutyn E
        • Hebel JR
        • et al.
        for the Infectious Diseases Society of America (IDSA). Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women.
        Clin Infect Dis. 1999; 29: 745-758
        • Fihn SD
        Clinical practice. Acute uncomplicated urinary tract infection in women.
        N Engl J Med. 2003; 349: 259-266
        • Bacheller CD
        • Bernstein JM
        Urinary tract infections.
        Med Clin North Am. 1997; 81: 719-730
        • Foxman B
        Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs.
        Am J Med. 2002; 113: 5S-13S
        • Hooton TM
        Recurrent urinary tract infection in women.
        Int J Antimicrob Agents. 2001; 17: 259-268
        • Johnson CC
        Definitions, classification, and clinical presentation of urinary tract infections.
        Med Clin North Am. 1991; 75: 241-252
        • Reid G
        • Bruce AW
        • Cook RL
        • Llano M
        Effect on urogenital flora of antibiotic therapy for urinary tract infection.
        Scand J Infect Dis. 1990; 22: 43-47
        • Baerheim A
        • Larsen E
        • Digranes A
        Vaginal application of Lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women.
        Scand J Prim Health Care. 1994; 12: 239-243
        • Reid G
        • Bruce AW
        • Taylor M
        Influence of 3-day antimicrobial therapy and Lactobacillus vaginal suppositories on recurrence of urinary tract infections.
        Clin Ther. 1992; 14: 11-16
        • Reid G
        • Bruce AW
        • Taylor M
        Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections.
        Microecol Ther. 1995; 23: 32-45
        • Kontiokari T
        • Sundqvist K
        • Nuutinen M
        • et al.
        Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women.
        BMJ. 2001; 322: 1571
        • Borriello SP
        • Hammes WP
        • Holzapfel W
        • et al.
        Safety of probiotics that contain lactobacilli or bifidobacteria.
        Clin Infect Dis. 2003; 36: 775-880
        • Salminen MK
        • Tynkkynen S
        • Rautelin H
        • et al.
        Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.
        Clin Infect Dis. 2002; 35: 1155-1160
        • Boyle RJ
        • Robins-Browne RM
        • Tang ML
        Probiotic use in clinical practice: What are the risks?.
        Am J Clin Nutr. 2006; 83: 1256-1264
        • Cannon JP
        • Lee TA
        • Bolanos JT
        • Danziger LH
        Pathogenic relevance of Lactobacillus: A retrospective review of over 200 cases.
        Eur J Clin Microbiol Infect Dis. 2005; 24: 31-40
      4. US Dept of Health and Human Services, Food and Drug Administration. 21 CFR Part 111.
        in: Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Fed Regist.72. 2007: 34,752-34,958 (Accessed February 27, 2008)